Get startedLog in
    Picture of Palvella Therapeutics logo

    PVLA — Palvella Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    All News

    Brief: Pieris Pharmaceuticals Announces Dosing Of First Subject In Phase 1 Trial Of Inhaled Ctgf Inhibitor PRS-220

    Picture of Palvella Therapeutics logoPalvella Therapeutics
    01/11/2022 14:34
    Nov 1 (Reuters) - Pieris Pharmaceuticals Inc  PIRS.O :
    * PIERIS PHARMACEUTICALS ANNOUNCES DOSING OF FIRST SUBJECT
IN
PHASE 1 TRIAL OF INHALED CTGF INHIBITOR PRS-220

Source text for Eikon: [https://bit.ly/3Wng2VU]
Further company coverage:  PIRS.O 
 ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Palvella Therapeutics

    See all news